Effect of Shampakadi Kwatha in the management of Vatrakta w.s.r to Hyperuricemia

A clinical study to evaluate the effect of Shampakadi Kwatha in the management of Vatrakta w.s.r. to Hyperuricemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049163

Enrollment

Registered

2023-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases Health Condition 2: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of either gender in the age group between 20-70 years. 2) Patients having serum uric acid level level more than 7mg/dl (male) and more than 6mg/dl (female) with or without any associated features of joint inflammation.

Exclusion criteria

Exclusion criteria: 1) Patient not willing for the trial. 2) Patient below age of 20 years and above 70 years of age. 3) Patient suffering from any other form of arthritis like osteoarthritis, Tubercular arthritis, Rheumatoid etc. 4) Patient suffering from chronic renal, respiratory, cardiac and hepatic disorders. 5)Patient having malignant disorder. 6) Patients who has completed participation in any other clinical trial during the past 3 months. 7) Any condition which the investigator thinks may comprise with the safety of the subject.

Design outcomes

Primary

Measure	Time frame
To evaluate the clinical efficacy of Shampakadi Kwatha in the management of Vatarakta w.s.r. to Hyperuricemia. Relief in symptoms of Vatrkata after intervention of Shampakadi kwatha Sandhishoola-joint pain Sandhishotha-Sweling of the joint Raga/Redness Twakavaivarnya/discoloration of skin Sparasashyata/tenderness Vidaha- Burning sensation Timepoint: Duration of trial : 6 weeks Follow up : After every 2 weeks till the completion of trial Dosage : Shampakadi kwatha â?? 50 ml Twice a day Route of administration : Oral	—

Measure

Time frame

To evaluate the clinical efficacy of Shampakadi Kwatha in the management of Vatarakta w.s.r. to Hyperuricemia. Relief in symptoms of Vatrkata after intervention of Shampakadi kwatha Sandhishoola-joint pain Sandhishotha-Sweling of the joint Raga/Redness Twakavaivarnya/discoloration of skin Sparasashyata/tenderness Vidaha- Burning sensation Timepoint: Duration of trial : 6 weeks Follow up : After every 2 weeks till the completion of trial Dosage : Shampakadi kwatha â?? 50 ml Twice a day Route of administration : Oral

—

Secondary

Measure	Time frame
To assess the clinical safety and adverse effects of Shampakadi Kwath. Improving quality of lifeTimepoint: At the 4weeks, 6 weeks and remain connected with telephonically to know the A.D.Rs if there is any after completion of trial	—

Countries

India

Contacts

Public ContactDr Anu Devi

RGGPG Ayu. Colllege Paprola HP

drmsony@gmail.com9816842425

Outcome results